Literature DB >> 1706986

Long term treatment of duodenal ulcer. A review of management options.

G Bianchi Porro1, F Parente.   

Abstract

Duodenal ulcer is a chronic disease characterised by remission and relapses. The duration of this relapsing tendency is unpredictable for the individual patient, but in most cases it lasts for many years and perhaps the entire lifetime. Various therapeutic strategies have been suggested to maintain the disease in remission: continuous, intermittent and on-demand treatment with H2-antagonists, or surgery. Continuous maintenance treatment with the currently available H2-blockers has proved to be superior to all the other strategies in terms of efficacy, and should therefore be regarded as the long term treatment of choice for duodenal ulcer patients. The duration of maintenance treatment is still uncertain, but probably it should not be less than a few years. Intermittent treatment or surgery could be proposed to patients unsuitable for continuous maintenance, depending on whether they have mild or aggressive disease, respectively.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1706986     DOI: 10.2165/00003495-199141010-00004

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  68 in total

1.  A post-investigation of 687 medically treated cases of peptic ulcer.

Authors:  H MALMROS; T HIERTONN
Journal:  Acta Med Scand       Date:  1949

2.  Cigarettes, alcohol, coffee and peptic ulcer.

Authors:  G D Friedman; A B Siegelaub; C C Seltzer
Journal:  N Engl J Med       Date:  1974-02-28       Impact factor: 91.245

Review 3.  Review: post-marketing surveillance of the safety of cimetidine--the problems of data interpretation.

Authors:  D G Jones; M J Langman; D H Lawson; M P Vessey
Journal:  Aliment Pharmacol Ther       Date:  1987-06       Impact factor: 8.171

4.  Conventional versus on-demand therapy for duodenal ulcer: results of a controlled therapeutic trial.

Authors:  V K Thorat; S P Misra; B S Anand
Journal:  Am J Gastroenterol       Date:  1990-03       Impact factor: 10.864

5.  Comparison of tri-potassium di-citrato bismuthate tablets with ranitidine in healing and relapse of duodenal ulcers.

Authors:  F I Lee; I M Samloff; M Hardman
Journal:  Lancet       Date:  1985-06-08       Impact factor: 79.321

6.  The operated stomach: a premalignant condition? A prospective endoscopic follow-up study.

Authors:  G J Offerhaus; K Huibregtse; J de Boer; T Verhoeven; G H van Olffen; J van de Stadt; G N Tytgat
Journal:  Scand J Gastroenterol       Date:  1984-06       Impact factor: 2.423

7.  Highly selective vagotomy and duodenal ulcers that fail to respond to H2 receptor antagonists.

Authors:  J N Primrose; A T Axon; D Johnston
Journal:  Br Med J (Clin Res Ed)       Date:  1988-04-09

8.  Relative effectiveness and costs of antiulcer medications as a basis for rational prescribing.

Authors:  A J McLean; D M Harcourt; P G McCarthy; F J Dudley; J J McNeil
Journal:  Med J Aust       Date:  1987-04-20       Impact factor: 7.738

9.  Controlled trial of maintenance cimetidine treatment in healed duodenal ulcer: short and long-term effects.

Authors:  M W Dronfield; A J Batchelor; W Larkworthy; M J Langman
Journal:  Gut       Date:  1979-06       Impact factor: 23.059

10.  The natural history of peptic ulcer disease: the influence of H2-antagonist treatment.

Authors:  G Bianchi Porro; M Petrillo
Journal:  Scand J Gastroenterol Suppl       Date:  1986
View more
  4 in total

Review 1.  Ranitidine: a pharmacoeconomic evaluation of its use in acid-related disorders.

Authors:  J E Frampton; D McTavish
Journal:  Pharmacoeconomics       Date:  1994-07       Impact factor: 4.981

Review 2.  Optimizing acid suppression for treatment of acid-related diseases.

Authors:  R H Hunt; C Cederberg; J Dent; F Halter; C Howden; I N Marks; S Rune; R P Walt
Journal:  Dig Dis Sci       Date:  1995-02       Impact factor: 3.199

Review 3.  Prescribing policy for antiulcer treatment in the elderly.

Authors:  G Bianchi Porro; M Lazzaroni
Journal:  Drugs Aging       Date:  1993 Jul-Aug       Impact factor: 3.923

4.  The use of proprietary medicines by patients presenting with peptic ulcer haemorrhage.

Authors:  J F Marriott; P A Asquith; C J Shorrock
Journal:  Br J Clin Pharmacol       Date:  1993-05       Impact factor: 4.335

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.